Patents
US 8535718 B2: Dosage forms of bisphosphonates
- Granted
- 2013-09-17
- Filed
- 2012-07-09 application 13544377
- Type
- Utility · 12 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Provided is an oral dosage form comprising a bisphosphonate selected from the group consisting of a risedronate and salts thereof; an ethylenediaminetetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof; and a delayed release mechanism to deliver the risedronate and the EDTA in the lower gastrointestinal tract, wherein the oral dosage form is administered according to a scheduled dosing interval. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
Source: PVGPATDIS, file of 2026-04-10 (ipg130917.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Warner Chilcott Company, LLC 27 patents | US company or organization | Fajardo, PR | WARNER CHILCOTT COMPANY, LLC State business registration EXACT high confidence: identical full name and state WARNER CHILCOTT PLC SEC filer FUZZY low confidence: same name (legal endings aside), one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Richard John Dansereau | Cincinnati, OH | 11 | PVGPATDIS, file of 2026-04-10 | |
| David Burgio | Monroe, OH | 4 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/675 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P3/00 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2018-02-22 | Correction Corrective assignment to correct the us patent no. 8,050,873 previously recorded on reel 040183 frame 0129. assignor(s) hereby confirms the assignment. | WARNER CHILCOTT COMPANY, LLC signed 2015-12-31 | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED DUBLIN 17 | 45417/593 | PASDL, file of 2026-10-15 |
| 2016-09-29 | Assignment Assignment of assignor's interest | WARNER CHILCOTT COMPANY, LLC signed 2015-12-31 | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED DUBLIN 17 | 40183/129 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.